Dihydropyridines and atypical MDR: A novel perspective of designing general reversal agents for both typical and atypical MDR
Dihydropyridines and atypical MDR: A novel perspective of designing general reversal agents for both typical and atypical MDR
复制标题
DOI：
10.1016/j.bmc.2008.07.025
复制
发表时间：
2008-09-15
影响因子：
3.5
通讯作者：
Mehdipour, Ahmadreza
中科院分区：
文献类型：
--
作者：
Miri, Ramin;Mehdipour, Ahmadreza
多药耐药性（MDR）被定义为肿瘤细胞对化疗中常用的多种结构不同且功能不同的药物的细胞毒作用的抵抗力。 1,4-二氢吡啶 (DHP) 是 Ca2+ 通道阻滞剂的主要类别之一，并且已证明这些药物是癌症治疗中的一类新型耐药逆转剂。对 DHP 的 MDR 逆转作用的各种研究分析表明，它们可以成为设计对典型和非典型 MDR 同时有效的化合物的潜在类别。此外，还可以考虑 MDR 逆转的基本结构特征以及作为不利影响的 Ca2+ 通道阻断活性的进一步降低。 (C) 2008 Elsevier Ltd. 保留所有权利。
Multidrug resistance (MDR) is defined as resistance of tumor cells to the cytotoxic action of multiple structurally dissimilar and functionally divergent drugs commonly used in chemotherapy. 1,4-Dihydropyridines (DHPs) are one of the major classes of Ca2+ channel blockers, and it has been shown that these agents are a new class of drug resistance reversers in cancer treatment. Analysis of various investigations on MDR reversing effects of DHPs shows that they can be a potential class for designing compounds simultaneously effective on both typical and atypical MDR. Also, it is possible to include some considerations on essential structural features for MDR reversing and further decreasing of Ca2+ channel blocking activity as an adverse effect. (C) 2008 Elsevier Ltd. All rights reserved.